Page 1357 - Williams Hematology ( PDFDrive )

1332 Part X: Malignant Myeloid Diseases Chapter 86: Primary Myelofibrosis 1333

contributes to the erythrocytosis in polycythemia and contributes to 29. Kaufman S, Briere J, Bernard J: Familial myeloproliferative syndromes: Study of 6 fam-
the risk of evolution to AML. About 5 to 10 percent of patients with ilies and review of literature. Nouv Rev Fr Hematol 20:1, 1978.
509
primary myelofibrosis do not have a mutation in JAK2, CALR, or MPL. 30. Péres-Encinas M, Bello JL, Perez-Crespo S, et al: Familial myeloproliferative syndrome.
Am J Hematol 46:225, 1994.
These so-called “triple-negative” patients with myelofibrosis appear to 31. Kutty J, Ridell B: Epidemiology of the myeloproliferative disorders: Essential thrombo-
have a less favorable prognosis as do those whose neoplastic cells have cythaemia, polycythemia vera, and idiopathic myelofibrosis. Pathol Biol 49:164, 2001.
wild type CALR and an ASXL1 mutation. 509A 32. McNally RJ, Rowland D, Roman E, Cartwright RA: Age and sex distributions of haema-
tological malignancies in the U.K. Hematol Oncol 15:173, 1997.
Primary myelofibrosis in infants and children has a more varied 33. Ridell B, Carneskog J, Wedel H, et al: Incidence of chronic myeloproliferative disorders
pathobiology than in adults. Patients have been followed for decades in the city of Gotesborg, Sweden 1983–1992. Eur J Haematol 65:267, 2000.
510
without requiring significant treatment, and spontaneous remission 34. Phekoo KJ, Richards MA, Møller H, Schey SA: The incidence and outcome of mye-
511
has been described. Because of its variable course, conservative man- loid malignancies in 2,112 adult patients in southeast England. Haematologica 91:1400,
2006.
agement may be appropriate while the course of the disease is followed. 35. Mesa RA, Silverstein MN, Jacobsen SJ, et al: Population-based incidence and survival
figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmstead
County Study 1976–1995. Am J Hematol 61:10, 1999.
REFERENCES 36. Aksoy M, Erdem S, Dincol G: Two rare complications of chronic benzene poisoning:
Myeloid metaplasia and paroxysmal nocturnal hemoglobinuria. Blut 30:255, 1975.
1. Heuck G: Zwei Fälle von Leukämie mit eigenthümlichem Blut-resp Knochenmarksbe- 37. Hu H: Benzene-associated myelofibrosis. Ann Intern Med 106:171, 1987.
fund. Virchows Arch Pathol Anat Physiol Klin Med 78:475, 1879. 38. Tondel M, Perrson B, Carstensen J: Myelofibrosis and benzene exposure. Occup Med
2. Silverstein MN: Agnogenic Myeloid Metaplasia. Publishing Science, Boston, 1975. 45:31, 1995.
3. Mesa RA, Verstovsek S, Cervantes F, et al: Primary myelofibrosis (PMF), post poly- 39. Anderson RE, Hoshino T, Yamamoto T: Myelofibrosis with myeloid metaplasia in sur-
cythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofi- vivors of the atomic bomb in Hiroshima. Ann Intern Med 60:1, 1964.
brosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the 40. Glass DC, Schnatter AR, Tang G, et al: Risk of myeloproliferative disease and chronic
international working group for myelofibrosis research and treatment (IWG-MRT). myeloid leukaemia following exposure to low-level benzene in a nested case-control
Leuk Res 31:737, 2007. study of petroleum workers. Occup Environ Med 71:266, 2014.
4. Lichtman MA: Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid meta- 41. Rinsky RA, Smith AB, Hornung R, et al: Benzene and leukemia. An epidemiologic risk
plasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leu- assessment. N Engl J Med 316:1044, 1987.
kemia? Further thoughts on the nosology of the clonal myeloid disorders. Leukemia 42. Johnson GT, Harbison SC, McCluskey JD, Harbison RD: Characterization of cancer
19:1139, 2005. risk from airborne benzene exposure. Regul Toxicol Pharmacol 55:361, 2009.
5. James C, Ugo V, Le Couédic JP, et al: A unique clonal JAK2 mutation leading to consti- 43. Jacobson RS, Salo A, Fialkow PS: Agnogenic myeloid metaplasia: A clonal proliferation
tutive signalling causes polycythaemia vera. Nature 434:1144, 2005. of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189, 1978.
6. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 44. Kahn A, Bernard JF, Cottreau D, et al: A deficient G-6-PD variant with hemizygous
in human myeloproliferative disorders. Lancet 365:1054, 2005. expression in blood cells of a woman with primary myelofibrosis. Humangenetik 30:41,
7. Lundberg P, Karow A, Nienhold R, et al: Clonal evolution and clinical correlates of 1975.
somatic mutations in myeloproliferative neoplasms. Blood 123:2220, 2014. 45. Sato Y, Suda T, Suda J, et al: Multilineage expression of haemopoietic precursors with an
8. Barosi G: Myelofibrosis with myeloid metaplasia. Hematol Oncol Clin North Am abnormal clone in idiopathic myelofibrosis. Br J Haematol 64:657, 1986.
17:1211, 2003. 46. Kreipe H, Jaquet K, Falgner J, et al: Clonal granulocytes and bone marrow cells in the
9. Ward HP, Block MH: The natural history of agnogenic myeloid metaplasia (AMM) cellular phase of agnogenic myeloid metaplasia. Blood 78:1814, 1991.
and a critical evaluation of its relationship with myeloproliferative syndrome. Medicine 47. Tsukamoto N, Morita K, Maehara T, et al: Clonality in chronic myeloproliferative dis-
(Baltimore) 50:357, 1971. orders defined by X-chromosome linked probes. Br J Haematol 86:253, 1994.
10. Varki A, Lottenberg R, Griffith R, et al: The syndrome of idiopathic myelofibrosis. Med- 48. Buschle M, Janssen JWG, Drexler H, et al: Evidence for pluripotent stem cell origin of
icine (Baltimore) 62:353, 1983. idiopathic myelofibrosis: Clonal analysis of a case characterized by a N-ras gene muta-
11. Barosi G: Myelofibrosis with myeloid metaplasia. Hematol Oncol Clin North Am tion. Leukemia 2:658, 1988.
17:1211, 2003. 49. Lebowitz P, Papac R, Ghosh PK: Impaired retinoblastoma susceptibility (Rb) gene
12. Okamura T, Kinukawa N, Niho Y, Mizoguichi H: Primary chronic myelofibrosis: Clin- expression in agnogenic myeloid metaplasia. Blood 76(Suppl 1):236A, 1990.
ical and prognostic evaluation in 336 Japanese patients. Int J Hematol 73:194, 2001. 50. Reeder TL, Bailey RJ, Dewald GW, Tefferi A: Both B and T lymphocytes may be clonally
13. Cervantes F, Pereira A, Esteve J, et al: Idiopathic myelofibrosis: Initial features, evolution- involved in myelofibrosis with myeloid metaplasia. Blood 101:1981, 2003.
ary pattern and survival in a series of 106 patients. Med Clin North Am 109:651, 1997. 51. Popat U, Frost A, Liu E, et al: High levels of circulating CD34 cells, dacryocytes, clonal
14. Dupriez B, Morel P, Demory JL, et al: Prognostic factors in agnogenic myeloid metapla- hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid meta-
sia: A report on 195 cases with a new scoring system. Blood 88:1013, 1996. plasia from secondary myelofibrosis associated with pulmonary hypertension. Blood
15. Rupoli S, DaLio L, Sisti S, et al: Primary myelofibrosis: A detailed analysis of the clini- 107:3486, 2006.
copathologic variables influencing survival. Ann Hematol 68:205, 1994. 52. Delhommeau F, Dupont S, Tonetti C, et al: Evidence that the JAK2 G1849T (V617F)
16. Ozen S, Ferhanoglu B, Senocak M, Tüzüner N: Idiopathic myelofibrosis (agnogenic mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic
myeloid metaplasia). Leuk Res 21:125, 1997. myelofibrosis. Blood 109:71, 2007.
17. Landgren O, Goldin LR, Kristinsson SY, et al: Increased risks of polycythemia vera, 53. James C, Mazurier F, Dupont S, et al: The hematopoietic stem cell compartment of
essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogene-
11,039 patients with myeloproliferative neoplasms in Sweden. Blood 112:2199, 2008. ity. Blood 112:2429, 2008.
18. Shalev O, Goldfarb A, Ariel I, et al: Myelofibrosis in young adults. Acta Haematol 54. Wendling F, Varlet P, Charon M, Tambourin P: MPLV: A retrovirus complex inducing
70:396, 1983. an acute myeloproliferative leukemic disorder in adult mice. Virology 149:242, 1986.
19. Sekhar M, Prentice HG, Poyat U, et al: Idiopathic myelofibrosis in children. Br J Haematol 55. Kaushansky K: Thrombopoietin. N Engl J Med 339:746, 1998.
93:394, 1996. 56. Yan X-Q, Lacey D, Hill D, et al: A model of myelofibrosis and osteosclerosis in mice
20. Cervantes F, Barosi G, Demory JL, et al: Myelofibrosis with myeloid metaplasia in induced by overexpressing thrombopoietin (mpl ligand). Blood 88:402, 1996.
young individuals: Disease characteristics, prognostic factors and identification of risk 57. Villeval JL, Cohen-Solal K, Tuliez M, et al: High thrombopoietin production by
groups. Br J Haematol 102:684, 1998. hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90:4396,
21. Sieff CA, Malleson P: Familial myelofibrosis. Arch Dis Child 55:888, 1980. 1997.
22. Sheikha A: Fatal familial infantile myelofibrosis. J Pediatr Hematol Oncol 26:164, 2004. 58. Chagraoui H, Komura E, Tulliez M, et al: Prominent role of TGF-beta 1 in thrombopoietin-
23. Rossbach HC: Familial infantile myelofibrosis as an autosomal recessive disorder: Pre- induced myelofibrosis in mice. Blood 100:3495, 2002.
ponderance among children from Saudi Arabia. Pediatr Hematol Oncol 23:453, 2006. 59. Chagraoui H, Tulliez M, Smayra T, et al: Stimulation of osteoprotegerin production is
24. Cohn SL, Cohn RA, Chou P, et al: Infantile myelofibrosis with nephromegaly secondary responsible for osteosclerosis in mice overexpressing TPO. Blood 101:2983, 2003.
to myeloid metaplasia. Clin Pediatr (Phila) 30:59, 1991. 60. Pikman Y, Lee BH, Mercher T, et al: MPLW515L is a novel somatic activating mutation
25. Mallouh AA, Sa’di AR: Agnogenic myeloid metaplasia in children. Am J Dis Child in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270, 2006.
146:965, 1992. 61. Vannucchi AM, Lasho TL, Guglielmelli P, et al: Mutations and prognosis in primary
26. Cervantes F, Barosi G, Hernández-Boluda J-C, et al: Myelofibrosis with myeloid meta- myelofibrosis. Leukemia 27:1861, 2013.
plasia in adult individuals 30 years old or younger: Presenting features, evolution and 62. Cazzola M, Kralovics R: From Janus kinase 2 to calreticulin: The clinically relevant
survival. Eur J Haematol 66:324, 2001. genomic landscape of myeloproliferative neoplasms. Blood 123:3714, 2014.
27. Segel GB, Lichtman MA: Familial (inherited) leukemia, lymphoma, and myeloma. 63. Vannucchi AM, Bianchi L, Cellai C, et al: Development of myelofibrosis in mice genet-
Blood Cells Mol Dis 32:246, 2004. ically impaired for GATA-1 expression (GATA-1(low) mice). Blood 100:1123, 2002.
28. Rumi E: Familial chronic myeloproliferative disorders: The state of the art. Hematol 64. Vannucchi AM, Migliaccio AR, Paoletti F, et al: Pathogenesis of myelofibrosis with mye-
Oncol 26:131, 2008. loid metaplasia: Lessons from mouse models of the disease. Semin Oncol 32:365, 2005.

Kaushansky_chapter 86_p1319-1340.indd 1332 9/18/15 10:24 AM